Clinical Trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07235059) titled 'Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease' on Nov. 14.

Brief Summary: The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.

Study Start Date: Nov. 18

Study Type: INTERVENTIONAL

Condition: Chronic Kidney Disease

Intervention: DRUG: OJR520

Participants will receive OJR520 in different dose levels.

OTHER: Placebo

Participants will receive OJR520 matching placebo.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Novartis Pharmaceuticals

Published by HT Digital Content Ser...